COMPANY
Akelos Inc.
The company currently is developing non-narcotic drugs for the treatment of neuropathic pain. From company website Source · Oct 12, 2026
NIH awards 2
- NIH award 5R42NS129370-02 FY2023: $349,409 awarded for that fiscal year; activity R42 (STTR); PI FOX, STEVEN R; recipient as written: AKELOS INC., NEW YORK, NY. Optimization of an HCN1-Selective Inverse Agonist for t source ↗
- NIH award 1R42NS129370-01 FY2022: $349,409 awarded for that fiscal year; activity R42 (STTR); PI FOX, STEVEN R; recipient as written: AKELOS INC., NEW YORK, NY. Optimization of an HCN1-Selective Inverse Agonist for t source ↗